Albany, NY -- (SBWIRE) -- 04/27/2020 -- Diabetic Gastroparesis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Diabetic Gastroparesis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total Diabetic Gastroparesis prevalent population in the 7MM is expected to rise to 17,859,995 in 2030.
2. About 40% of patients with Type 1 Diabetes have Gastroparesis.
3. Around 30% of Type 2 Diabetes Mellitus (DM) cases suffer from Diabetic Gastroparesis.

Key benefits of the report
1. Diabetic Gastroparesis market report covers a descriptive overview and comprehensive insight of the Diabetic Gastroparesis epidemiology and Diabetic Gastroparesis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Diabetic Gastroparesis market report provides insights on the current and emerging therapies.
3. Diabetic Gastroparesis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Diabetic Gastroparesis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diabetic Gastroparesis market.

Request for sample pages

"Market Size of Diabetic Gastroparesis in the 7MM is expected to reach USD 4331.47 million by 2030."

The usual Diabetic Gastroparesis treatments include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents. The first line of management is focused on optimization of glycemic control known as dietary therapy in addition to the prokinetic therapy in order to improve gastric emptying and gastroparesis symptoms.

The prokinetic therapies include Reglan, which is approved by the FDA. However, Motillum another prokinetic drug is also used as a viable treatment option in cases which do not respond to the former. Some symptomatic therapies such as Phenothiazines, Serotonin 5-HT3 Receptor Antagonists and Antihistamines are used as well.

Symptomatic treatment includes Erythromycin, which is a macrolide antibiotic with an agonist effect on motilin receptors in the gastrointestinal tract that increases gastric emptying in a dose-response fashion. Oral doses are administered in combination with a low bulk diet, and it also plays its part in generating a significant amount of revenue for the Diabetic Gastroparesis treatment.

Gastric Electrical Stimulation (GES) is a procedural therapy used for a subset of patients with severe. GES enhances nausea, vomiting, quality of life and nutritional status in patients with refractory Diabetic Gastroparesis and tends to attract a particular market share.

The launch of the emerging therapies is expected to significantly impact Diabetic Gastroparesis treatment scenario in the upcoming years:-
Drugs covered
1. Relamorelin
2. Metoclopramide Nasal Spray (Gimoti)
3. Velusetrag
4. Sepiapterin (CNSA-001)
5. CIN-102
And many others

The key players in Diabetic Gastroparesis market are:
1. Allergan
2. Evoke Pharma Inc
3. Theravance Biopharma
4. Censa Pharmaceuticals
5. CinDome Pharma
And many others

Table of contents
1 Key Insights
2 Executive Summary
3 SWOT Analysis for Diabetic Gastroparesis
4 Diabetic Gastroparesis Market Overview at a Glance
5 Diabetic Gastroparesis Disease Background and Overview
6 Diabetic Gastroparesis Epidemiology and Patient Population
7 Country Wise-Epidemiology of Diabetic Gastroparesis
7.1 The United States
7.2 EU5
7.3 Germany
7.4 France
7.5 Italy
7.6 Spain
7.7 The United Kingdom
7.8 Japan
8 Diabetic Gastroparesis Treatment and Management
9 Case study for Diabetic Gastroparesis
10 Unmet Needs
11 Diabetic Gastroparesis Marketed Drugs
11.1 Metoclopramide: ANI Pharmaceuticals, Inc
12 Diabetic Gastroparesis Emerging Therapies
12.1 Relamorelin: Allergan
12.2 Metoclopramide Nasal Spray (Gimoti): Evoke Pharma Inc.
12.3 Velusetrag: Theravance Biopharma
12.4 Sepiapterin (CNSA-001): Censa Pharmaceuticals
12.5 CIN-102: CinDome Pharma
13 Other products of interest
13.1 TAK-954: Takeda (Millennium Pharmaceuticals, Inc.)
13.2 TAK-906: Takeda (Millennium Pharmaceuticals, Inc.)
13.3 Nimacimab: Bird Rock Bio
14 Diabetic Gastroparesis: 7 Major Market Analysis
15 Market Outlook by Country
15.1 United States: Market Outlook
15.2 The United States Market Size
16 EU-5 Countries: Market Outlook
16.1 Germany
16.2 France
16.3 Italy
16.4 Spain
16.5 The United Kingdom
17 Japan: Market Outlook
18 Market Access and Reimbursement Overview of Diabetic Gastroparesis
20 Market Drivers
21 Market Barriers
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight